Optimization of regimes of mobilization of blood hemopoietic stem cells in patients with multiple myeloma
- 作者: Pokrovskaya O.1, Mendeleeva L.1, Urnova E.1, Gaponova T.1, Gribanova E.1, Alekseeva I.1, Drokov M.1, Kalinin N.1, Gretsov E.1, Klyasova G.1, Savchenko V.1, Pokrovskaya O2, Mendeleeva L2, Urnova E2, Gaponova T2, Gribanova E2, Alekseeva I2, Drokov M2, Kalinin N2, Gretsov E2, Klyasova G2, Savchenko V2
-
隶属关系:
- ФГБУ Гематологический научный центр Минздравсоцразвития России
- Hematological Research Center, Moscow
- 期: 卷 83, 编号 7 (2011)
- 页面: 50-57
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30886
- ID: 30886
如何引用文章
全文:
详细
Material and methods. Department of hemoblastoses chemotherapy and bone marrow transplantation of the Russian Hematological Center performed mobilization of autologous blood hemopoietic stem cells (BHSC) in 93 MM patients treated in 2001-2010. This was done with cyclophosphamide and G-CSF. The former was used in 59 cases in a dose 6 g/m2, in 34 cases - 4 g/m2.
Results. Myelotoxic agranulocytosis after cyclophosphamide administration developed in all the patients and was observed for 3-10 days (median 5 days). Agranulocytosis ran without documented infections in 51 (54.8%) patients, with febril fever - in 42 (45.2%) patients. Cepticemia, pneumonia, necrotic enteropathy, stomatitis, herpetic lesion of the skin were registered in 9, 4, 11, 14 and 6 cases, respectively. Severe thrombocytopenia (< 30x109/l) occurred more frequently in administration of 6 g/ m2 cyclophosphamide. It was corrected with 2-5 transfusions of thromboconcentrates, only 1 transfusion was needed after the dose 4 g/m2.
Collection of CD34+ cells started in leukocyte level over 3.5x109/l on mobilization day 12-20 (median day 15). The day of the first leukocytapheresis did not depend on the day of the first introduction of G-CSF. Duration of G-CSF administration was significantly shorter in the start of its use after leukocyte count decrease under 1.0x109/l. Conduction of 1 to 5 (median 2) leukocytapheresis was needed for collection of BHSC. Sufficient for 2 autotransplantations number of BHSC were stored in 90 of 93 patients. Cyclophosphamide administration in a dose 6 g/m2 allowed collection of cells sufficient for one autotransplantation for the first leukapheresis in 52 (88.1) patients. A total number of CD34+ cells over 4x106 cells/kg were collected in 56 (94.9%) patients. In administration of cyclophosphamide in a dose 4 g/m2 mobilization was effective in all 34 patients. The first leukapheresis provided sufficient for one autotransplantation number of cells in 29 (85.3%) patients.
Conclusion. Administration of high cyclophosphamide doses in combination with G-CSF is an effective and safe method of BHSC mobilization providing collection of adequate number of CD34+ cells for double autotransplantation in 96.8% patients. Cost effective is the start of G-CSF administration in the fall of leukocytes under 1.0x109/l. Cyclophosphamide dose 4 g/m2 provides collection of CD34+ cells number sufficient for two autotransplantations in moderate thrombocytopenia and in less number of substitute transfusions in the absence of serious toxic complications.
作者简介
Ol'ga Pokrovskaya
ФГБУ Гематологический научный центр Минздравсоцразвития России
Email: sillywilly@yandex.ru
науч. сотр. лаб. криоконсервирования костного мозга и биологии стволовых клеток ГНЦ, тел.: 8-495-614-90-42; ФГБУ Гематологический научный центр Минздравсоцразвития России
Larisa Mendeleeva
ФГБУ Гематологический научный центр Минздравсоцразвития России
Email: mlp@blood.ru
д-р мед. наук, вед. науч. сотр. отд-ния химиотерапии гемобластозов и трансплантации костного мозга ГНЦ; ФГБУ Гематологический научный центр Минздравсоцразвития России
Evdokiya Urnova
ФГБУ Гематологический научный центр Минздравсоцразвития России
Email: eurnova@mail.ru
врач отд-ния трансплантации костного мозга ГНЦ; ФГБУ Гематологический научный центр Минздравсоцразвития России
Tat'yana Gaponova
ФГБУ Гематологический научный центр Минздравсоцразвития России
Email: gaponova.tatj@yandex.ru
зав. лаб. криоконсервирования костного мозга и биологии стволовых клеток ГНЦ; ФГБУ Гематологический научный центр Минздравсоцразвития России
Elena Gribanova
ФГБУ Гематологический научный центр Минздравсоцразвития России
Email: gribanova@blood.ru
канд. мед. наук, зав. отд-нием химиотерапии гемобластозов и трансплантации костного мозга ГНЦ; ФГБУ Гематологический научный центр Минздравсоцразвития России
Inna Alekseeva
ФГБУ Гематологический научный центр Минздравсоцразвития России
Email: inna_alekseeva@blood.ru
врач отд-ния трансплантации костного мозга ГНЦ; ФГБУ Гематологический научный центр Минздравсоцразвития России
Mikhail Drokov
ФГБУ Гематологический научный центр Минздравсоцразвития России
Email: mdrokov@gmail.com
клинический ординатор отд-ния трансплантации костного мозга ГНЦ; ФГБУ Гематологический научный центр Минздравсоцразвития России
Nikolay Kalinin
ФГБУ Гематологический научный центр Минздравсоцразвития России
Email: kalininn@blood.ru
д-р мед. наук, проф., рук. отд-ния экстракорпорального очищения крови ГНЦ; ФГБУ Гематологический научный центр Минздравсоцразвития России
Evgeniy Gretsov
ФГБУ Гематологический научный центр Минздравсоцразвития Россииврач КДЛ функциональной морфологии гемобластозов ГНЦ, тел.: 8-495-612-51-71; ФГБУ Гематологический научный центр Минздравсоцразвития России
Galina Klyasova
ФГБУ Гематологический научный центр Минздравсоцразвития России
Email: klias@blood.ru
д-р мед. наук, зав. лаб. микробиологии, микологии и антибактериальной терапии ГНЦ; ФГБУ Гематологический научный центр Минздравсоцразвития России
Valeriy Savchenko
ФГБУ Гематологический научный центр Минздравсоцразвития России
Email: svg@blood.ru
чл.-кор. РАМН, д-р мед. наук, проф., дир. Ин-та молекулярной гематологии и трансплантации костного мозга ГНЦ; ФГБУ Гематологический научный центр Минздравсоцразвития России
O Pokrovskaya
Hematological Research Center, MoscowHematological Research Center, Moscow
L Mendeleeva
Hematological Research Center, MoscowHematological Research Center, Moscow
E Urnova
Hematological Research Center, MoscowHematological Research Center, Moscow
T Gaponova
Hematological Research Center, MoscowHematological Research Center, Moscow
E Gribanova
Hematological Research Center, MoscowHematological Research Center, Moscow
I Alekseeva
Hematological Research Center, MoscowHematological Research Center, Moscow
M Drokov
Hematological Research Center, MoscowHematological Research Center, Moscow
N Kalinin
Hematological Research Center, MoscowHematological Research Center, Moscow
E Gretsov
Hematological Research Center, MoscowHematological Research Center, Moscow
G Klyasova
Hematological Research Center, MoscowHematological Research Center, Moscow
V Savchenko
Hematological Research Center, MoscowHematological Research Center, Moscow
参考
- Alexanian R., Weber D., Giralt S. et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001; 27(10): 1037- 1043.
- Lahuerta J. J., Mateos M. V., Martinez-Löpez J. et al. Influence of pre- and posttransplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J. Clin. Oncol. 2008; 26(35): 5775-5782.
- Van de Velde H. J. K., Liu X., Chen G. et al. Complete response correlates with long-term survival and progresiön-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92(10): 1399-1406.
- Harousseau J. L., Attal M., Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009 ; 114: 3139- 3146.
- Ludwig H., Beksac M., Blade J. et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010; 15: 6-25.
- Alvares C. L., Davies F. E., Horton C. et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006; 91: 141-142.
- Olin R. L., Vogl D. T., Porter D. L. et al. Second auto-SCT is safe and effective salvage therapy for relapsed myltiple myeloma. Bone Marrow Transplant. 2009; 43(5): 417-422.
- The Joint Accreditation Committee of ISСТ-ЕURОРЕ and EBMT. Standards for hematopoietic progenitor cell collection, processing and transplantation. 2-nd ed. Istanbul; 2003.
- Bensinger W., Appelbaum F., Rowley S. et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J. Clin. oncol. 1995; 13: 2547-2555.
- Desikan K. R., Tricot G., Munshi N. C. et al. Preceding chemotherapy, tumor load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br. J. Haematol. 2001; 112(1): 242-247.
- Kumar S., Giralt S., Stadtmauer E. et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib- containing regimens. Blood 2009; 114(9): 1729-1735.
- Rubia J., Blade J., Lahuerta J.-J. et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) study. Haematologica 2006; 91(5) 621-627.
- Hiwase D. K., Bollard G., Hiwase S. et al. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 2007; 9(6): 539-547.
- Goldschmidt H., Hegenbart U., Haas R. et al. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colonystimulating factor in patients with multiple myeloma. Bone Marrow Transplant. 1996; 17(5): 691-697.
- Kotasek D., Shepherd K. M., Sage R. E. et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilisation in lymphoma, myeloma, and solid tumors. Bone Marrow Transplant 1992; 9: 11-17.
- Fitoussi О., Perreau V., Boiron J. M. et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant. 2001; 27(8): 837-842.
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 2003; 121(5): 749-757.
- Durie B. G. M., Harousseau J.-L., Miguel J. S. et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20(9): 1467-1473.
- Goldschmidt H., Hegenbart U., Wallmeier M. et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br. J. Haematol. 1997; 98: 736-744.
- Prince H. M., Imrie K., Sutherland D. R. et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br. J. Haematol. 1996; 93(1): 142-145.
- Менделеева Л. П., Савченко В. Г., Павлова О. А. и др. Мобилизация гранулоцитарным колониестимулирующим фактором аутологичных гемопоэтических клеток крови у больных лимфомами и раком молочной железы. Пробл. гематол. 1999; 4: 5-12.
- Зубаровская Л. С., Семенова Е. В., Бабенко Е. В. и др. Эффективность мобилизации периферических стволовых клеток крови с помощью препарата лейкостим у больных злокачественными новообразованиями. Онкогематология 2008; 1: 70-75.
- Bensinger W., DiPersio J. F., McCarty J. M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009; 43: 181-195.
- Менделеева Л. П., Покровская О. С., Урнова Е. С. и др. Мобилизация препаратом филграстима - граногеном аутологичных гемопоэтических стволовых клеток у больных с онкогематологическими заболеваниями. Гематол. и трансфузиол. 2009; 3: 31-36.
- Менделеева Л. П., Митиш Н. Е., Клясова Г. А. и др. Инфекционные осложнения после трансплантации аутологичных гемопоэтических клеток при гемобластозах. Тер. apx. 2005; 7: 33-39.
- Кос O. N., Gerson S. L., Cooper B. W. et al. Randomized cross-over trail of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J. Clin. Oncol. 2000; 18(9): 1824-1830.
- Jantunen E., Putkonen M., Nousiainen T. et al. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilization in patients with multiple myeloma. Bone Marrow Transplant. 2003; 31: 347-351.